• Latest Oral Insulin Drug Making Its Way To Clinical Trials

    Bio-IT World | More than a century has passed since the discovery of insulin, the world's first life-saving treatment for diabetes, and it is still being delivered via injection despite several brushes with success in developing an oral version of the drug. Hope is again on the horizon with the emergence of an oral nanotherapeutic formulation of insulin that comes with the possibility of reducing if not eliminating hypoglycemic events.

    Feb 20, 2024

  • New Vaccinology Rulebook Needed To Outsmart ‘Part-Time Pathogens’

    Bio-IT World | Researchers at University of California San Diego School of Medicine have found that the rules of vaccinology need to be reversed for Staphylococcus aureus (SA), the common and sometimes dangerous bacteria that humans encounter shortly after birth and are continuously exposed to for the remainder of their life.

    Feb 15, 2024

  • Study Establishes ENPP1 As A Biomarker For Immunotherapy Benefit

    Bio-IT World | Researchers in California have shown that breast cancer patients with RNA expression levels of ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) in the bottom 50th percentile can confidently be treated with Keytruda (pembrolizumab) as well as surgery. Their cancer would have a zero percent chance of metastasizing in seven years.

    Feb 14, 2024

  • Novel NGS-Based Assay Has Seemingly Limitless Virus Detection Potential

    Bio-IT World | Scientists at the Center for Infection and Immunity (CII) at Columbia University Mailman School of Public Health have created a next-generation sequencing (NGS) technology that employs oligonucleotides (oligos)—short single strands of synthetic DNA—as bait for relevant targets of detection.

    Feb 13, 2024

  • GenAI’s Real Potential in Biopharma: As a Cross-Function R&D Assistant

    Bio-IT World | In biopharma R&D there is growing momentum around the use of Generative AI, the deep-learning algorithms capable of distilling complex knowledge into easily digestible summaries. But so far companies have been relatively modest in their ambitions for the technology.

    Feb 9, 2024

  • New Patient Scoring Method To Enable Precision Medicine For Chronic Diseases

    Bio-IT World | Investigators with The University of New Mexico (UNM) and the National Institutes of Health (NIH) have succeeded in developing a cholesterol-lowering vaccine that works independently of statins. It could become the next vaccine-based approach targeting PCSK9 (proprotein convertase subtilisin/kexin type 9 serine protease) to enter clinical trials.

    Feb 7, 2024

  • Pharmaceutical Targets Identified For Osteoarthritis

    Bio-IT World | Investigators with The University of New Mexico (UNM) and the National Institutes of Health (NIH) have succeeded in developing a cholesterol-lowering vaccine that works independently of statins. It could become the next vaccine-based approach targeting PCSK9 (proprotein convertase subtilisin/kexin type 9 serine protease) to enter clinical trials.

    Feb 6, 2024

  • Becky Upton on Effective Data Management, Setting Standards, and Teamwork

    Bio-IT World | Scientists at the Center for Infection and Immunity (CII) at Columbia University Mailman School of Public Health have created a next-generation sequencing (NGS) technology that employs oligonucleotides (oligos)—short single strands of synthetic DNA—as bait for relevant targets of detection.

    Feb 1, 2024

  • Illumina Venture Labs Now Operational, Oxford Nanopore Expands Pilot Program, New Chief Portfolio Officer at Pistoia Alliance, More

    Bio-IT World | Illumina Ventures Labs is now operational and finalizing agreements with several startup companies; Oxford Nanopore Technologies and Guy’s and St Thomas’ NHS Foundation Trust have successfully completed a pilot program meant to deliver a respiratory metagenomics service with an integrated respiratory infection and biosecurity application; The Pistoia Alliance has appointed Dr. Christian Baber as its new Chief Portfolio Officer; more.

    Jan 31, 2024

  • Follow the Money: Biomedical Research Program, Depression Treatment Implant Device, AI Advancements, More

    Bio-IT World | The University of New England has received an award from the National Institutes of Health to support an Institutional Development Award Center of Biomedical Research Excellence to be named the UNE Center for Cell Signaling Research; Motif Neurotech has secured a Series A financing for the development of lead product, DOT microstimulator; Ex-Nvidia exec launches and intends to further develop AI platform RagaAI; more.

    Jan 30, 2024

  • Two-In-One Cholesterol-Lowering Vaccine Now Ready For Clinical Testing

    Bio-IT World | Investigators with The University of New Mexico (UNM) and the National Institutes of Health (NIH) have succeeded in developing a cholesterol-lowering vaccine that works independently of statins. It could become the next vaccine-based approach targeting PCSK9 (proprotein convertase subtilisin/kexin type 9 serine protease) to enter clinical trials.

    Jan 25, 2024

  • ‘Opioid Of The Masses’ Used To Make Therapies For Neurodegenerative Diseases

    Bio-IT World | Taking a cue from Mother Nature, researchers from The University of Texas at El Paso are exploring the use of carbon nanoparticles synthesized from caffeic acid found in coffee grounds as a preventative or therapeutic agent for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Their work marks the first time caffeic acid has been used to create carbon quantum dots and the approach is not only economical and sustainable but also potentially interventional.

    Jan 24, 2024

  • Protein Signatures Of Organ Aging Could Aid Disease Prevention Efforts

    Bio-IT World | Stanford Medicine investigators are leading the development of a test measuring organ-specific proteins in the blood as a simple and sensible way to estimate biological age. Among the potential applications are screening people for conditions such as heart failure and Alzheimer’s disease, personalizing the intervention they’re prescribed, and signaling sooner the efficacy of investigational drugs based on how well they rejuvenate certain organs.

    Jan 23, 2024

  • Research Suggests New Immunopreventive Approach To Tackling Cancer

    Bio-IT World | The lifetime probability of being diagnosed with an invasive cancer is estimated to be roughly 40% for both men and women, and there’s a strong possibility that they are all, in some sense, preventable. Scientific evidence suggests that the body’s immune system copes with the “internal danger” of tumor development the same way it deals with the external threat of infectious diseases.

    Jan 18, 2024

  • JP Morgan Healthcare on Acquisitions, AI Advancements, More

    Bio-IT World | At this year’s JP Morgan Healthcare conference, biotech and diagnostic companies and experts provided overviews of 2023 accomplishments and their goals for 2024. We’ve covered presentations by NVIDIA, Regeneron, Illumina, Pacific Biosciences, and Oxford Nanopore in depth. Here we list highlights from Pfizer, Moderna, Eli Lilly, Thermo Fisher, and more.

    Jan 17, 2024

  • Oxford Nanopore at JP Morgan: Native DNA Advantage

    Bio-IT World | CEO Gordan Sanghera gave Oxford Nanopore’s first live presentation at the JP Morgan Healthcare Conference last week. He highlighted his platforms accuracy and the company’s consumable growth.

    Jan 16, 2024

  • PacBio at JP Morgan: Revio, Onso, Three Sequencing Platforms in Development

    Bio-IT World | Christian Henry, President and CEO of Pacific Biosciences, was unabashedly cheerful at the JP Morgan Healthcare Conference on Wednesday afternoon when he gave the updates for PacBio. “2023 absolutely exceeded our expectations,” he said, basking in two platform launches, strong consumable growth, and three new platforms in development.

    Jan 12, 2024

  • Illumina at JP Morgan: Tighter Focus, Consumable Growth, Short Read Market

    Bio-IT World | CEO Jacob Thaysen presented Illumina’s updates yesterday at the JP Morgan Healthcare Conference. 2023 has been an eventful year for the sequencing pioneer with December’s announcement that Illumina would divest GRAIL; Francis deSouza, Illumina’s former CEO, stepping down in June; and $175M in cost cuts over the course of 2023 which included headcount reductions and major real estate changes. Thaysen presented Illumina at a turning point.

    Jan 10, 2024

  • The LOWE Down on Recursion’s New LLM Orchestration Work Engine from JP Morgan

    Bio-IT World | Chris Gibson, CEO of Recursion, launched a live demo of Recursion’s new large language model orchestration work engine, LOWE, yesterday at the JP Morgan Healthcare Conference. The tool is the next step toward Recursion’s goal of autonomous drug discovery.

    Jan 9, 2024

  • NVIDIA at JP Morgan: Generative AI and the Computer Aided Drug Design Tipping Point

    Bio-IT World | Drug design is at a tipping point, Kimberly Powell, vice president of Healthcare for NVIDIA, argued in her Monday morning presentation at the JP Morgan Healthcare Conference. “Two necessary conditions have arrived for drugs: digitizing biology and being able to represent it in a computer. We have the perfect conditions to see a massive expansion of this computer-aided drug discovery industry,” she said. And generative AI is the class of tools that will facilitate it.

    Jan 8, 2024